Offers genetic tests for hereditary cancer, cardiology, neurology, and pediatrics. Provides genetic testing for oncology, metabolic conditions, and rare diseases. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 37% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
An investor who bought at the very peak is down 80% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 37% a year on average.
The company sells $516.3M a year; the problem isn’t sales — it’s costs running above that number.
It met or beat analyst expectations in 6 of the last 7 quarters — consistency is a promise kept.
A loss of $3.1B against $516.3M in annual sales.
The stock sits at $0.02. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.